184 related articles for article (PubMed ID: 35301806)
1. Conditional survival of trimodal therapy for nonmetastatic muscle-invasive bladder cancer: A SEER database analysis.
Shangguan W; Hu J; Xie Y; Chen Z; Zhong Q; Zheng Z; Zhu D; Zhang Y; Yang J; Han J; Xie W
Cancer Med; 2022 Jun; 11(12):2356-2365. PubMed ID: 35301806
[TBL] [Abstract][Full Text] [Related]
2. Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
Tang Y; Lin L; Xiao Y; Meng L; Yang Y; Li X
Clin Transl Oncol; 2024 Feb; 26(2):446-455. PubMed ID: 37389736
[TBL] [Abstract][Full Text] [Related]
3. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
4. Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy.
de Angelis M; Scheipner L; Siech C; Jannello LMI; Baudo A; Bello FD; Goyal JA; Vitucci K; Tian Z; Longo N; Ahyai S; de Cobelli O; Chun FKH; Saad F; Shariat SF; Carmignani L; Gandaglia G; Moschini M; Montorsi F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2024 Aug; 22(4):102119. PubMed ID: 38852435
[TBL] [Abstract][Full Text] [Related]
5. Prognostic variations between 'primary' and 'progressive' muscle-invasive bladder cancer following radical cystectomy: a novel propensity score-based multicenter cohort study.
Lai S; Liu J; Lai CH; Seery S; Hu H; Wang M; Hu H; Xu T
Int J Surg; 2024 Jan; 110(1):270-279. PubMed ID: 37738002
[TBL] [Abstract][Full Text] [Related]
6. Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time.
Ploussard G; Shariat SF; Dragomir A; Kluth LA; Xylinas E; Masson-Lecomte A; Rieken M; Rink M; Matsumoto K; Kikuchi E; Klatte T; Boorjian SA; Lotan Y; Roghmann F; Fairey AS; Fradet Y; Black PC; Rendon R; Izawa J; Kassouf W
Eur Urol; 2014 Aug; 66(2):361-70. PubMed ID: 24139235
[TBL] [Abstract][Full Text] [Related]
7. Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy.
Kool R; Marcq G; Shinde-Jadhav S; Mansure JJ; Saleh R; Rajan R; Aprikian A; Tanguay S; Cury FL; Brimo F; Souhami L; Kassouf W
Eur Urol Open Sci; 2022 Feb; 36():26-33. PubMed ID: 35098169
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer.
Zhiyu Z; Qi Z; Zhen S; Jun O; Jianglei Z
Technol Cancer Res Treat; 2021; 20():15330338211062323. PubMed ID: 34816789
[No Abstract] [Full Text] [Related]
10. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM
JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
Seisen T; Sun M; Lipsitz SR; Abdollah F; Leow JJ; Menon M; Preston MA; Harshman LC; Kibel AS; Nguyen PL; Bellmunt J; Choueiri TK; Trinh QD
Eur Urol; 2017 Oct; 72(4):483-487. PubMed ID: 28412065
[TBL] [Abstract][Full Text] [Related]
12. Bladder preservation in older adults with muscle-invasive bladder cancer: A retrospective study with concurrent chemotherapy and twice-daily hypofractionated radiotherapy schedule.
Alati A; Fabiano E; Geiss R; Mareau A; Charles-Nelson A; Bibault JE; Giraud P; Kreps S; Méjean A; Housset M; Durdux C
J Geriatr Oncol; 2022 Sep; 13(7):978-986. PubMed ID: 35717533
[TBL] [Abstract][Full Text] [Related]
13. HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: a retrospective cohort study.
Kim SW; Yu H; Kim Y; Nam KH; Chae HK; Nam W; Eom DW; Park JY; Kim SJ
Int J Surg; 2024 Feb; 110(2):847-858. PubMed ID: 37916931
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for conditional survival in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.
Kang M; Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
Sci Rep; 2015 Jul; 5():12171. PubMed ID: 26212449
[TBL] [Abstract][Full Text] [Related]
15. Role of Maximal Transurethral Resection Preceding Partial Cystectomy for Muscle-Invasive Bladder Cancer.
Ham WS; Park JS; Jang WS; Kim J
Ann Surg Oncol; 2024 Feb; 31(2):1384-1392. PubMed ID: 37884699
[TBL] [Abstract][Full Text] [Related]
16. Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis.
Su X; Dong C; Liao W; Liu W
World J Surg Oncol; 2023 Aug; 21(1):271. PubMed ID: 37641150
[TBL] [Abstract][Full Text] [Related]
17. Treatment Allocation and Survival in Patients Diagnosed with Nonmetastatic Muscle-invasive Bladder Cancer: An Analysis of a National Patient Cohort in England.
John JB; Varughese MA; Cooper N; Wong K; Hounsome L; Treece S; McGrath JS; Harden S
Eur Urol Focus; 2021 Mar; 7(2):359-365. PubMed ID: 32088138
[TBL] [Abstract][Full Text] [Related]
18. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
19. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.
Mak KS; Smith AB; Eidelman A; Clayman R; Niemierko A; Cheng JS; Matthews J; Drumm MR; Nielsen ME; Feldman AS; Lee RJ; Zietman AL; Chen RC; Shipley WU; Milowsky MI; Efstathiou JA
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1028-1036. PubMed ID: 27727064
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
